Fig. 2From: Findings from a pilot open-label trial of N-acetylcysteine for the treatment of pediatric mania and hypomaniaBar graph depiction of percent of participants with CGI-I scores ≤ 2 for anxiety, ADHD, and ODD, ranging from 12% for ADHD to 27% for ODDBack to article page